Newsroom

Download PDF AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio CAMBRIDGE, Mass. Jan. 04, 2007 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd. an exclusive license to develop and commercialize Kirin’s highly potent

Download PDF CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase inhibitor of EGFR/HER2.  The open-label, sequential dose escalation study

Download PDF – Contract Follows Successful Human Engineering™ of AV-299 – Berkeley, CA and Cambridge, MA — September 28th, 2006 – Xoma Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced a $6 million agreement for XOMA to manufacture and supply AV-299, AVEO’s novel anti-HGF antibody, in support of early clinical trials.  The companies also

Download PDF CAMBRIDGE, MA (September 27, 2006) – The Web Marketing Association (“WMA”) today announced that it has awarded its “Pharmaceutical Industry Standard of Excellence” WebAward for 2006 to AVEO Pharmaceuticals – a biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. The website was designed, implemented, and launched in 2006 by Embarc,

Download PDF – Human Engineering™ Technology to Accelerate Development of Clinical Candidate – Berkeley, CA and Cambridge, MA — April 27, 2006 — XOMA Ltd. (Nasdaq: XOMA) and AVEO Pharmaceuticals, Inc. (AVEO) today announced an agreement for XOMA to utilize its Human Engineering™ (HE™) technology to humanize AV-299, AVEO’s novel anti-HGF monoclonal antibody.  For work conducted and

Download PDF – Human-in-Mouse (HIM) system represents breakthrough in modeling of human breast cancer –  – HIM system offers potential for significantly improved predictability in preclinical drug testing – CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that is has

Download PDF – AV-412, a novel EGFR/HER2 kinase inhibitor, demonstrates potent anti-tumor activity against both Tarceva® and Iressa®-sensitive and resistant tumors – – AV-412 holds promise as a broader-acting EFGR/HER2 inhibitor – CAMBRIDGE, MA April 4, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today

Download PDF Palo Alto, Calif. – March 30, 2006 – Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), a leading debt and equity growth capital provider to technology and life science companies, announced on March 29, 2006 it provided $15.0 million of debt financing to AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development